Breaking News

Novo Nordisk Exits Inflammatory R&D

Will focus efforts on diabetes prevention and treatment

Novo Nordisk has decided to discontinue all R&D activities within inflammatory disorders and will increase efforts within diabetes prevention and treatment, obesity and diabetes complications.
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters